Chen Feifan, Wang Robin H, Lullo Jenna J, Cadden Sarah B, Koster Hunter, Schaeffer Jackson, Speiser Jodi J
Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, IL.
Department of Dermatology, Loyola University Medical Center, Maywood, IL; and.
Am J Dermatopathol. 2025 Sep 23. doi: 10.1097/DAD.0000000000003135.
Mycosis fungoides bullosa is a rare clinical subtype of mycosis fungoides, with less than 40 cases reported in the literature. We report a case of a 66-year-old female with a history of stage IIB folliculotrophic mycosis fungoides with large cell transformation, currently being treated with romidepsin and gemcitabine, transferred to our institution due to worsening cutaneous involvement. On exam, there were large, erythematous, crusted and eroded plaques of the neck, trunk, and bilateral upper and lower extremities, some with overlying tense bullae. Punch biopsy showed a marked infiltrate of atypical CD3+ lymphocytes with epidermotropism of predominantly CD4+ cells (CD4:CD8 ratio of 8:1), loss of CD5 and CD7, and scattered CD30+ cells. Direct immunofluorescence showed a non-diagnostic staining pattern. Blood cultures were negative. Given the clinical and histopathologic findings, a diagnosis of mycosis fungoides bullosa was made. Mycosis fungoides is the most common type of cutaneous T-cell lymphoma. Mycosis fungoides bullosa, a vesiculobullous presentation of mycosis fungoides, is a rare variant first described by Dr. Moritz Kaposi in 1887. Proposed mechanisms of bullae formation include confluence of Pautrier's microabscesses or loss of keratinocyte cohesion due to proliferation of atypical lymphocytes. Diagnosis is based on the presence of vesiculobullous lesions among typical lesions of mycosis fungoides, histopathologic features consistent with mycosis fungoides, and negative evaluation for other causes of vesiculobullous lesions such as infection and autoimmune blistering diseases. Recognition is important as mycosis fungoides bullosa carries poor prognosis, with 50% of reported patients expiring within 1 year of bullae appearance.
大疱性蕈样肉芽肿是蕈样肉芽肿一种罕见的临床亚型,文献报道病例不足40例。我们报告一例66岁女性,有IIB期毛囊性蕈样肉芽肿伴大细胞转化病史,目前正在接受罗米地辛和吉西他滨治疗,因皮肤受累加重转入我院。查体可见颈部、躯干及双侧上下肢有大片红斑、结痂及糜烂斑块,部分有张力性大疱。穿刺活检显示非典型CD3 +淋巴细胞显著浸润,以CD4 +细胞向表皮浸润为主(CD4:CD8比例为8:1),CD5和CD7缺失,散在CD30 +细胞。直接免疫荧光显示非诊断性染色模式。血培养阴性。根据临床和组织病理学表现,诊断为大疱性蕈样肉芽肿。蕈样肉芽肿是最常见的皮肤T细胞淋巴瘤类型。大疱性蕈样肉芽肿是蕈样肉芽肿的水疱大疱性表现,是一种罕见的变异型,最早由莫里茨·卡波西博士于1887年描述。大疱形成的推测机制包括Pautrier微脓肿融合或非典型淋巴细胞增殖导致角质形成细胞黏附丧失。诊断基于蕈样肉芽肿典型皮损中存在水疱大疱性损害、与蕈样肉芽肿一致的组织病理学特征,以及对水疱大疱性损害的其他病因如感染和自身免疫性疱病的阴性评估。认识到这一点很重要,因为大疱性蕈样肉芽肿预后较差,据报道50%的患者在出现大疱后1年内死亡。